Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J 
Welcome,         Profile    Billing    Logout  

36 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Remicade (infliximab) / J&J
2014-002311-41: A prospective randomized controlled trial comParing infliximAb-antimetabolites combination therapy to anti-metabolites monotheraPy and infliximab monothErapy in Crohn's disease patients in sustained steroid-free remission on combination therapy

Ongoing
4
300
Europe, RoW
INFLIXIMAB, Azathioprine, Methotrexate, Mercaptopurine, Infusion, Tablet, Concentrate and solvent for cutaneous solution, Remicade, Imuran, Methotrexate, Mercaptopurine
GETAID, University of Edinburgh, GETAID, European Union, Horizon 2020 framework program for research and innovation
Luminal Crohn's disease patients in steroid free remission for at least 6 months and on combination therapy with infliximab and antimetabolites for at least 1 year, Luminal Crohn's disease patients in steroid free remission for at least 6 months and on combination therapy with infliximab and antimetabolites for at least 1 year, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
 
 
2017-001970-41: Dose reduction and withdrawal of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months multi-centre trial

Ongoing
4
180
Europe
Abatacept, Adalimumab, Certolizumab pegol, Etanercept, Golimumab, Infliximab, Tocilizumab, L04AA24, L04AB04, L04AB05, L04AB01, L04AB06, L04AB02, L04AC07, Concentrate for solution for injection, Concentrate and solvent for solution for infusion, Concentrate and solvent for solution for injection, Concentrate and solvent for suspension for injection, Orencia, Humira, Cimzia, Enbrel, Benepali, Simponi, Remsima, Remicade, RoActemra, Inflectra, Imraldi, Amgevita
MD, PhD Salome Kristensen, The Danish Regions (Regionernes Medicinpulje), The Department of Rheumatology at Aalborg University Hospital, Health Science Research Fund of the Region of Northern Jutland
Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis (arthritis of the spine), Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2018-002925-47: prediction of response to therapy in inflammatory bowel disease Predicción de respuesta al tratamiento en la enfermedad inflamatoria intestinal

Not yet recruiting
4
180
Europe
Injection, Infusion, Adalimumab, Infliximab, Golimumab, Ustekinumab, Vedolizumab
Fundación de Investigación Biomédica del Hospital Universitario de La Princesa, Instituto de Salud Carlos III
Inflammatory bowel disease Enfermedad inflamatoria intestinal, Corhn´s disease and ulcerative colitis Enfermedad de Crohn y colitis ulcerosa, Diseases [C] - Digestive System Diseases [C06]
 
 
2018-002064-15: Patient preference model: treatment of perianal fistulas in Crohn's disease

Ongoing
4
140
Europe
Infliximab, Adalimumab, Powder for concentrate and solution for solution for infusion, Powder for concentrate for solution for infusion, Remicade, Humira
Academic Medical Center, Academic Medical Center
Perianal fistulas in Crohn's Disease, Perianal fistulas in Crohn's Disease, Diseases [C] - Digestive System Diseases [C06]
 
 
2018-004587-61: Characterization of lipid changes in patients with ulcerative colitis treated with tofactinib or infliximab Karakteriseren van veranderingen die optreden in vetten bij patiënten met colitis ulcerosa tijdens de behandeling met tofacitinib of infliximab

Ongoing
4
40
Europe
Tofacitinib, Infliximab, Film-coated tablet, Concentrate and solvent for solution for infusion, Xeljanz, Inflectra
Erasmus Medical Center, Erasmus Medical Center, Pfizer
Ulcerative colitis Colitis ulcerosa, Chronic inflammatory bowel disease of the large intestine and rectum Chronische ontstekingsziekte van de dikke darm en endeldarm, Diseases [C] - Digestive System Diseases [C06]
 
 
NCT02517684 / 2014-005702-37: Top-down Infliximab Study in Kids With Crohn's Disease

Completed
4
100
Europe
Infliximab, Inflectra, Prednisolone, Exclusive enteral nutrition, Azathioprine, Imuran
Erasmus Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Hospira, now a wholly owned subsidiary of Pfizer
Crohn's Disease
12/19
01/24
2021-002211-65: EFFECT OF TOFACITINIB ON COAGULATION EFECTO DE TOFACITINIB SOBRE LA COAGULACIÓN

Ongoing
4
60
Europe
Injection, Infusion, Pastille, Adalimumab, Infliximab, Golimumab, Tofacitinib
Fundación Española de Gastroenterología, pfizer
ulcerative colitis colitis ulcerosa, ulcerative colitis colitis ulcerosa, Body processes [G] - Biological Phenomena [G16]
 
 
FREE, NCT04646187 / 2020-001811-26: De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease

Enrolling by invitation
4
148
Europe
Infliximab, Remicade, Flixabi, Inflectra, Remsima, Zessly, Adalimumab, Humira, AMGEVITA, Hulio, Hyrimoz, Idacio, Imraldi
University Medical Center Groningen, European Crohn´s and Colitis Organisation, Bühlmann Laboratories AG
Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative
03/25
03/25
POMEROL, NCT05072782: Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the Trial.

Recruiting
4
360
Europe
Infliximab CT-P13, Remsima, Immunosuppressors (Thiopurines or Methotrexate)
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, Celltrion
Crohn Disease
06/23
06/24
TITRATE, NCT03937609 / 2018-003524-36: (inducTIon for acuTe ulceRATivE Colitis)

Recruiting
4
120
Europe
Infliximab, Remicade, Inflectra and Remsima
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Pfizer
Colitis, Ulcerative
12/24
12/24
RECAST, NCT05164198: REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis

Not yet recruiting
4
448
NA
Adalimumab and its biosimilars, Humira, Adaloce, Biological: Etanercept and its biosimilars, Enbrel, Eucept, Etalace, Golimumab, Simponi, Infliximab biosimilar, Remsima
Hanyang University Seoul Hospital, Linical Korea
Ankylosing Spondylitis, Axial Spondyloarthritis
10/24
10/24
NCT05906576: Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients

Recruiting
4
30
RoW
Infliximab, CMAB008
Taizhou Mabtech Pharmaceutical Co.,Ltd
Crohn Disease
11/26
02/27
2018-001811-59: This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

Not yet recruiting
3
1050
Europe
durvalumab, MEDI4736, Concentrate for solution for infusion, Remicade 100mg powder for concentrate for solution for infusion, Celicept 250mg Capsules, Micofenolato Mofetile, Mycophenolate mofetil Sandoz 250 mg, Inflectra 100 mg powder for concentrate for solution for infusion
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder, Muscle Invasive Bladder Cancer (T2-T4a) in stage II and IIIA without lymph node involvement, Diseases [C] - Cancer [C04]
 
 
REACH3, NCT03112603 / 2016-004432-38: A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation

Checkmark Data from REACH3 trial for acute GVHD at ASH 2020
Dec 2020 - Dec 2020: Data from REACH3 trial for acute GVHD at ASH 2020
Checkmark Data from REACH3 trial in steroid-refractory chronic GVHD
Jul 2020 - Jul 2020: Data from REACH3 trial in steroid-refractory chronic GVHD
Completed
3
330
Europe, Canada, Japan, US, RoW
Ruxolitinib, Jakafi, INCB018424, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Incyte Corporation
Graft-versus-host Disease (GVHD)
05/20
12/22
2019-004652-11: A Study of Etrolizumab-Based Induction Therapy Combinations Followed by Etrolizumab Maintenance Therapy in Patients with Moderate-To-Severe Ulcerative Colitis

Ongoing
3
372
Europe
Etrolizumab, RO5490261/F04-02, Solution for injection in pre-filled syringe, Powder for concentrate for solution for infusion, Film-coated tablet, Concentrate for solution for infusion, Remicade, Xeljanz, Stelara
F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Ulcerative Colitis (UC), UC is a chronic disease of the large intestine, in which the lining of the colon becomes inflamed and develops tiny open sores, or ulcers, Diseases [C] - Digestive System Diseases [C06]
 
 
NCT04505410: Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis

Completed
3
32
US
Tofacitinib, Fast Mimicking Diet, Ustekinumab induction, Infliximab induction
University of Miami, Pfizer
Ulcerative Colitis
12/23
12/23
CATCO, NCT04330690: Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

Active, not recruiting
3
2900
Canada
Artesunate, Imatinib, Infliximab, Dexamethasone, LSALT Peptide
Sunnybrook Health Sciences Centre, AbbVie, Apotex Inc., World Health Organization, University of British Columbia, Arch Biopartners Inc.
COVID-19
03/24
05/24
PURSUIT 2, NCT03596645 / 2017-004496-31: A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting
3
84
Europe, US, RoW
Golimumab, Infliximab
Janssen Research & Development, LLC
Colitis, Ulcerative
11/23
08/27
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting
3
60
Europe, Canada, Japan, US, RoW
Mirikizumab IV, LY3074828, Mirikizumab SC
Eli Lilly and Company
Ulcerative Colitis
07/26
03/27
REMODEL-CD, NCT05660746: Precise Infliximab Exposure and Pharmacodynamic Control

Recruiting
2/3
180
US
RoadMAB, Infliximab, Avsola, Inflectra, Ixifi, Remicade, Renflexis
Children's Hospital Medical Center, Cincinnati, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Janssen Scientific Affairs, LLC
Crohn Disease
03/27
03/27
2017-003311-19: Phase IIa proof-of-principle study for the induction treatment of autoimmune hepatitis using infliximabAIH-MAB Phase IIa proof-of-principle Studie zur Wirksamkeit von Infliximab in der Induktionstherapie der Autoimmunen Hepatitis

Ongoing
2
12
Europe
Concentrate for solution for infusion, Inflectra (Infliximab)
University Medical Centre Hamburg-Eppendorf, University Medical Centre Hamburg-Eppendorf
Autoimmune Hepatitis (AIH); rare inflammatory liver disease associated with elevated transaminases, elevated Immunoglobulin G, the presence of autoantibodies and interface hepatitis in liver histology. Untreated, AIH progresses to liver fibrosis and cirrhosis with its complications. Historical placebo-controlled studies could show a mortality of around 70% in the placebo-treated group. Die Autoimmune Hepatitis ist eine chronische Entzündung der Leber, die durch eine Reaktion des Immunsystems gegen körpereigenes Lebergewebe ausgelöst wird. Die Ursachen hierfür sind bisher unklar. Die Behandlung der autoimmunen Hepatitis besteht in der Therapie mit sogenannten Immunsuppressiva, also Medikamenten, die das körpereigene Immunsystem schwächen und so die Reaktion gegen das körpereigene Lebergewebe unterdrücken., Autoimmune Hepatitis (AIH) is rare inflammatory liver disease caused by unknown triggers. Untreated, AIH progresses to to liver fibrosis and cirrhosis with its complications Die Autoimmune Hepatitis ist eine chronische Entzündung der Leber, die durch eine Reaktion des Immunsystems gegen körpereigenes Lebergewebe ausgelöst wird. Die Ursachen hierfür sind bisher unklar., Diseases [C] - Immune System Diseases [C20]
 
 
2019-004336-31: This is a phase II, open-label, multi-centre study to determine the safety and tolerability of durvalumab in patients with non-small cell lung cancer who were treated with radiation therapy but are ineligible for chemotherapy Il s'agit d'une étude de phase 2 internationale, multicentrique, à un seul groupe, en ouvert visant à évaluer l'activité clinique du durvalumab chez des patients atteints de CPNPC de stade III non résécable qui sont considérés comme non éligibles à la chimiothérapie.

Not yet recruiting
2
150
Europe
Durvalumab, MEDI4736, Concentrate for solution for infusion, CellCept 250 mg capsule, Remicade
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Patients with Stage III unresectable Non-small cell lung cancer (NSCLC), who have an Eastern Cooperative Oncology Group (ECOG) PS of 0 to 2 and who are treated with radiotherapy but are ineligible for chemotherapy patients atteints de CPNPC de stade III non résécable qui sont considérés comme non éligibles à la chimiothérapie, A specific type of lung cancer type spécifique de cancer du poumon, Diseases [C] - Cancer [C04]
 
 
INFLIXCOVID, NCT04922827 / 2021-002098-25: Infliximab in the Treatment of Patients With Severe COVID-19 Disease

Completed
2
9
Europe
Infliximab, Standard of Care
Jena University Hospital, German Federal Ministry of Education and Research, Celltrion
COVID-19
03/23
07/23
RAPID-I, NCT03684278: Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial

Recruiting
2
290
Europe
Infusion of 5 mg/kg Infliximab, Remicade, Infusion of 10 mg/kg Infliximab, 0.9% Sodium Chloride (Placebo)
University of Liverpool, Bangor University, Liverpool University Hospitals NHS Foundation Trust, Medical Research Council, National Institute for Health Research, United Kingdom, Merck Sharp & Dohme LLC
Acute Pancreatitis
07/26
03/27
BALDER, NCT06075706: Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

Recruiting
2
48
Europe
MC0518, BAT
medac GmbH
Steroid-refractory Acute Graft-versus-host Disease
08/26
06/31
2019-002186-36: Treatment of acute graft-versus-host disease after allogeneic stem cell transplantation with placenta derived decidua stroma cells (DSC) compared with best available treatment (BAT).

Ongoing
1/2
56
Europe
Decidua Stroma Cells, DSC, L01XE18, L04AA, L04AX03, L04AA06, L01XE10, L04AA10, L04AB01, L04AB02, Solution for injection/infusion, , Powder and solution for solution for injection, Tablet, Powder and solvent for dispersion for injection, Solution for blood fraction modification, Jakavi, Entyvio, Methotrexate, Cellcept, Afinitor, Rapamune, Enbrel, Remicade, Extracorporeal photophersis, Methoxalen
Uppsala University Hospital, Swedish Research Council
Steroid refractory acute GVHD Kortison refraktär akut GVHD, Acute graft-versus-host reaction after allogeneic stem cell transplantation not responding to steroid treatment. Akut transplantat-mot-värd reaktion som inte svarar på kortison behandling., Diseases [C] - Immune System Diseases [C20]
 
 
PEREM, NCT04990258: A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC

Active, not recruiting
N/A
444
Europe
Subcutaneous infliximab CT-P13 Remsima®SC
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, Celltrion
Inflammatory Bowel Diseases
06/24
09/24
NCT04312659: A Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease

Completed
N/A
38
RoW
Infliximab
Johnson & Johnson (China) Investment Ltd.
Crohn Disease
09/23
09/23
NCT05014555: Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease

Not yet recruiting
N/A
400
US
COVID-19 Vaccine
GI Alliance, Janssen, LP, University of Wisconsin, Madison, Mayo Clinic
Inflammatory Bowel Diseases
01/24
01/24
POPS or POP02, NCT04278404: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Recruiting
N/A
5000
Canada, US
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:, Aminocaproic acid, Amiodarone, Bosentan, Budesonide, Cefdinir, Cefepime, Ceftazidime, Clindamycin, Clobazam, Dexamethasone, Dexmedetomidine, Dextroamphetamine/Amphetamine, Fosfomycin, Furosemide, Gabapentin, Guanfacine, Hydrocortisone, Labetalol, Meropenem, Metformin, Milrinone, Nalbuphine, Nicardipine, Nifedipine, Oseltamivir, Oxycodone, Risperidone, Sertraline, Sevelamer Carbonate / Sevelamer Hydrochloride, Spironolactone, Terbutaline, Tranexamic acid, Voriconazole, Zolpidem, Azithromycin, Lopinavir/Ritonavir, Ribavirin, Tocilizumab, Anakinra, Aspirin, Canakinumab, Colchicine, Interferon, Remdesivir, Ruxolitinib, Sarilumab, Abatacept, Infliximab
Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
09/26
09/27
NCT05430412: CT to Assess the Efficacy and Safety of Adding GMA to Infliximab in Paediatric Patients With Steroid-refractory Ulcerative Colitis

Recruiting
N/A
15
Europe
Adacolumn
Adacyte Therapeutics SL, Adknoma Health Research
Ulcerative Colitis
10/24
10/24
COMMIT, NCT05702879: Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success

Recruiting
N/A
240
Europe
Ozanimod, TNF Inhibitor, infliximab, adalimumab, etanercept, golimumab, and certolizumab., Steroids, Prednisolon, Vedolizumab, Ustekinumab
Insel Gruppe AG, University Hospital Bern, Bristol-Myers Squibb
Ulcerative Colitis
01/25
01/25
NCT04372108: A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

Recruiting
N/A
1056
US
Ustekinumab, Other Biologic Therapies
Janssen Scientific Affairs, LLC
Crohn Disease, Colitis, Ulcerative
08/29
08/30
PSOLAR, NCT00508547: Psoriasis Longitudinal Assessment and Registry

Checkmark in the treatment of psoriasis
May 2016 - May 2016: in the treatment of psoriasis
Checkmark PSOLAR (ACR-ARHP 2015)
Oct 2015 - Oct 2015: PSOLAR (ACR-ARHP 2015)
Checkmark P4 data (PSOLAR)
More
Active, not recruiting
N/A
15842
Europe, Canada, Japan, US, RoW
Janssen Scientific Affairs, LLC
Psoriasis
12/29
12/30
NCT01848028: PsoBest - The German Psoriasis Registry

Recruiting
N/A
3500
Europe
Universitätsklinikum Hamburg-Eppendorf, Berufsverband der Deutschen Dermatologen e.V. (www.bvdd.de), Deutsche Dermatologische Gesellschaft e.V. (https://derma.de), AbbVie, Biogen, Janssen-Cilag G.m.b.H, medac GmbH, Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, Pfizer Pharmaceuticals Ltd., Merck Serono GmbH, Germany, PsoNet.eu (http://www.psonet.eu/), Celgene, Eli Lilly and Company, Amgen, Almirall Hermal GmbH, UCB Pharma, Bristol-Myers Squibb, Viatris Inc., LEO Pharma
Psoriasis, Psoriatic-arthritis
12/32
12/32
DEVELOP, NCT00606346: A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Checkmark ESPGHAN: Crohns disease (DEVELOP)
May 2014 - May 2014: ESPGHAN: Crohns disease (DEVELOP)
Active, not recruiting
N/A
4970
Canada, US
Anti TNF therapy including infliximab, No Biologics
Janssen Biotech, Inc.
Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Diseases
11/37
06/38

Download Options